• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconWegovy

Wegovy

Page 4 of 7
Angela Fitch. cofounder and chief medical officer of knownwell.
Commentary
I’m an obesity medicine doctor and I’ve been on weight-loss drugs like Ozempic for a decade. Here’s why I think they aren’t a fad
By Angela FitchJuly 30, 2024
Thomas Schinecker, chief executive officer of Roche
Finance
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
By Prarthana PrakashJuly 29, 2024
Obesity medicine physician Dr. Nisha Patel breaks down five weight loss myths that “need to die” with Fortune.
Health
The 5 biggest weight loss myths that ‘need to die,’ according to an obesity doctor
By Lindsey LeakeJuly 18, 2024
A bathroom scale is surrounded by colorful pills.
Health
Pharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots
By Damian Garde and BloombergJuly 11, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
Features
Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree
By Jessica Mathews and Alena BotrosJuly 9, 2024
Close-up of an Ozempic pen in a greenwash style
Health
Ozempic linked to rare cases of vision loss in Harvard study
By Robert Langreth and BloombergJuly 3, 2024
Lars Fruergaard Jorgensen, CEO of Novo Nordisk.
Health
A rare setback as Ozempic-maker Novo Nordisk takes a $820 million hit as its next wonder drug fails
By Naomi Kresge and BloombergJune 27, 2024
Novo Nordisk’s Wegovy may have just two years to take over China’s market for weight-loss drugs
Tech
Novo Nordisk’s Wegovy may have just two years to take over China’s market for weight-loss drugs
By Lionel LimJune 26, 2024
A photo of the packet for anti-obesity drug Wegovy.
Tech
India’s gray market is selling Wegovy at less than 10% of U.S. prices—even though weight-loss drugs aren’t officially available in the country
By Satviki Sanjay and BloombergJune 19, 2024
Baggy pants are out and smaller sizes are flying off the shelves as Wegovy changes how Americans buy clothes
Retail
Baggy pants are out and smaller sizes are flying off the shelves as Wegovy changes how Americans buy clothes
By Marco Quiroz-GutierrezJune 17, 2024
Ozempic and Wegovy are so hard to find that a startup invented a free tool for tracking whether the viral drugs are in stock
Health
Ozempic and Wegovy are so hard to find that a startup invented a free tool for tracking whether the viral drugs are in stock
By Marco Quiroz-GutierrezMay 29, 2024
‘My old doctor told me there was nothing he could do. He told me it was my fault’: Wegovy revolution sees 600% increase among young adults
Health
‘My old doctor told me there was nothing he could do. He told me it was my fault’: Wegovy revolution sees 600% increase among young adults
By Jonel Aleccia and The Associated PressMay 22, 2024
Dr. Razia Hashmi, vice president of clinical affairs, Blue Cross Blue Shield Association, speaks during Fortune’s Brainstorm Health conference in Dana Point, Calif., on Tuesday, May 21, 2024.
Health
GLP-1 drugs like Wegovy are all the rage—but people are quitting them too fast to achieve meaningful weight loss, finds 170,000-patient study
By Lindsey LeakeMay 22, 2024
Nestle CEO Mark Schneider
Retail
Nestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs
By Sasha RogelbergMay 21, 2024
Dr. Patrick Carroll (right), Hims & Hers chief medical officer, speaks during Fortune’s Brainstorm Health conference in Dana Point, Calif., Monday, May 20, 2024.
Conferences
Hims & Hers’ surprise 85% Wegovy discount is latest step on a journey to make medicine less ‘paternalistic,’ exec says
By Marco Quiroz-GutierrezMay 20, 2024
1
  • 2
  • 3
  • 4
  • 5
  • 6
7
Most Popular
Real Estate
The millennial generation has split, new Fed research shows: Those over 35 are edging toward boomer-style wealth, while everyone else falls behindplaceholder alt text
By Nick LichtenbergJuly 22, 2026
Success
Mark Cuban says he has the solution to growing income inequality, and it's to reward every employee—from CEO to janitor—with company stockplaceholder alt text
By Sasha RogelbergJuly 20, 2026
AI
Mathematicians grapple with a ‘very rapid and very unsettling change’ as AI cracks yet another century-old problemplaceholder alt text
By Eva RoytburgJuly 21, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.